Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma

International Journal of Radiation Oncology Biology Physics

Volumn 42, Issue 3, 1998, Pages 631-639

  Williams, Jeffery A ^a,c   Yuan, Xuan ^a   Dillehay, Larry E ^d   Shastri, Venkatram R ^b   Brem, Henry ^a   Williams, Jerry R ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d NONE

Author keywords

Biodegradable polymer; Human glioma; Iododeoxyuridine; Radiosensitization

Indexed keywords

BROXURIDINE; IDOXURIDINE; POLYANHYDRIDE; POLYMER; PROPANE; SEBACIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL LABELING; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG IMPLANT; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; LABELING INDEX; MALE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RADIOSENSITIZATION; SUBCUTANEOUS DRUG ADMINISTRATION; TUMOR XENOGRAFT;

ANIMALS; ANTIMETABOLITES; BRAIN NEOPLASMS; CELL DIVISION; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; GLIOBLASTOMA; HUMANS; IDOXURIDINE; MALE; MICE; MICE, NUDE; POLYMERS; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031751622     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00258-2     Document Type: Article

References (42)

1. McLaughlin P, Lawrence T, Seabury H, et al. Bromodeoxyuridine-mediated radiosensitization in human glioma: The effect of concentration, duration, and fluoropyrimidine modulation. Int J Radiat Oncol Biol Phys 1994; 30:601-607.
2. Uhl V, Phillips T, Ross G, et al. Iododeoxyuridine incorporation and radiosensitization in three human tumor cell lines. Int J Radiat Oncol Biol Phys 1992; 22:489-494.
3. Levin V, Prados M, Wara W, et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine, and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995; 32:75-83.
4. Erickson R, Szybalski W. Molecular radiobiology of human cell lines. V. Comparative radiosensitizing properties of 5-halodeoxycytidines and 5-halodeoxyuridines. Radiat Res 1963; 20:252-262.
5. Fornace A, Dobson P, Kinsella T. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys 1990; 18:873-878.
6. Lawrence T, Davis M, Maybaum J, et al. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys 1990; 18:1393-1398.
7. Goffinet D, Brown J. Comparison of intravenous and intraarterial pyrimidine infusion as a means of radiosensitizing tumors. Radiology 1977; 124:819-822.
8. Russo A, Gianni L, Kinsella T, et al. Pharmacological evaluation of intravenous delivery of 5-bromodeoxyuridine to patients with brain tumors. Cancer Res 1984; 44:702-1705
9. Jackson D, Kinsella T, Rowland J, et al. Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme. Am J Clin Oncol 1987; 10:437-443.
10. Kinsella T, Russo A, Mitchell J, et al. Phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys 1985; 11:1941-1946.
11. Kinsella T, Collins J, Rowlan J, et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 1988; 6:871-879.
12. Greenberg H, Chandler W, Ensminger W. Radiosensitization with carotid arterial infusion bromodeoxyuridine and external beam radiation for gliomas. In: Ensminger W, Selam J, editors. Update in drug delivery systems. Mount Kisco: Futura Publishing Co.; 1989. pp. 233-246.
13. Hegarty T, Thornton A, Diaz R, et al. Intra-arterial bromodeoxyuridine radiosensitization of malignant gliomas. Int J Radiat Oncol Biol Phys 1990; 19:421-428.
14. Wirtanen G, Wiley A, Vermund H, et al. Intraarterial iododeoxyuridine infusion combined with irradiation. A pilot study. Am J Clin Oncol 1990; 13:320-323.
15. Cook J, Glass J, Lebovics R, et al. Measurement of thymidine replacement in patients with high grade gliomas, head and neck tumors, and high grade sarcomas after continuous intravenous infusion of 5-iododeoxyuridine. Cancer Res 1992; 52:719-725.
16. Goffman T, Dachowsk L, Bobo H, et al. Long-term follow-up on national cancer institute phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol 1992; 10:264-268.
17. Urtasun R, Cosmatos D, DelRowe J, et al. Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: A comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 1993; 27:207-214.
18. Bagshaw MA, Doggett RS, Smith KC, et al. Intra-arterial 5-bromodeoxyuridine and x-ray therapy. Am J Roentgenol 1967; 4:886-894.
19. Phuphanich S, Levin EM, Levin VA. Phase I study of intravenous bromodeoxyuridine used concomitantly with radiation therapy in patients with primary malignant brain tumors. Int J Radiat Oncol Biol Phys 1984; 10:1769-1772.
20. Pollay M, Roberts P. Blood-brain barrier: A definition of normal and altered function. Neurosurgery 1980; 6:675-685.
21. Brem H. Polymers to treat brain tumors. Biomaterials 1990; 11:699-701.
22. Brem H, Piantadosi S, Burger P, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995; 345:1008-1012.
23. Walter K, Cahan M, Gur A, et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 1994; 54:2207-2212.
24. Domb A, Langer R. Polyanhydrides. I. Preparation of high molecular weight polyanhydrides. J Polymer Sci 1987; 25:3373-3386.
25. Gratzner H. Monoclonal antibody to 5-bromo-and 5-iododeoxyuridine: A new reagent for detection of DNA replication. Science 1982; 218:474-475.
26. Vanderlaan M, Thomas C. Characterization of monoclonal antibodies to bromodeoxyuridine. Cytometry 1985; 6:501-505.
27. Williams J, Klein J, Wanek P, et al. Quantitative intercomparison of radiolabeled antibodies and external beam radiotherapy in the treatment of human glioma xenografts in vivo. Int J Radiat Oncol Biol Phys 1992; 24:111-117.
28. Ritter M, Fowler J, Kim Y, et al. Single biopsy tumor kinetic analysis: A comparison of methods and an extension to shorter sampling intervals. Int J Radiat Oncol Biol Phys. 1992; 23:811-820.
29. Schutte B, Reynders M, Assche C. An improved method for the immunocytochemical detection of bromodeoxyuridine labeled nuclei using flow cytometry. Cytometry 1987; 8:372-378.
30. White R, Terry N. A quantitative method for evaluating bivariate flow cytometric data obtained using monoclonal antibodies to bromodeoxyuridine. Cytometry 1992; 13:490-495.
31. Fowler J, Lindstrom M. Loss of local control with prolongation in radiotherapy. Int J Radiat Oncol Biol Phys 1992; 23:457-467.
32. Hall EJ. Radiobiology for the radiologist. Philadelphia: Lippincott; 1994. p. 201.
33. Begg A, McNally N, Schrieve D, et al. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985; 6:620-626.
34. Norusis M. SPSS Advanced Statistics 6.1. Chicago: SPSS Inc.; 1994.
35. Perez LA, Dombkowski D, Efird J, et al. Cell proliferation kinetics in human tumor xenografts measured with iododeoxyuridine labeling and flow cytometry: A study of heterogeneity and a comparison between different methods of calculation and other proliferation measurements. Cancer Res 1995; 55:392-398.
36. Leong KW, Brott BC, Langer R. Bioerodible polyanhydrides as drug-carrier matrices. I: Characterization, degradation, and release characteristics. J Biomed Mater Res 1985; 19:941-955.
37. Tamada JA, Langer R. Erosion kinetics of hydrolytically degradable polymers. Proc Natl Acad Sci USA 1993; 90:552-556.
38. Budavari S, ed. The Merck Index. Whitehouse Station: Merck; 1996. p. 841.
39. Rodriguez R, Ritter M, Fowler J, et al. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int J Radiat Oncol Biol Phys 1994; 29:105-113.
40. Williams J, Dillehay L, Sipos E, et al. Implantable biodegradable polymers for radiosensitization of human glioma in vivo. J Neurooncol 1997; 32:181-192.
41. Ghosh MK, Mitra AK. Enhanced delivery of 5-iodo-2′-deoxyuridne to the brain parenchyma. Pharm Res 1992; 9:1173-1176.
42. Ghosh MK, Mitra AK. Brain parenchymal metabolism of 5-iodo-2′-deoxyuridine and 5′-ester prodrugs. Pharm Res 1992; 9:1048-1052.